In June, the Food and Drug Administration (FDA) approved bremelanotide (brand name Vyleesi) to treat a lack of sexual desire in premenopausal women.1 The NWHN advocated against the drug’s approval, and spoke in opposition when the approval announcement was made. Here’s why.
Bremelanotide (brand name: Vyleesi) is a drug approved by the FDA to treat a lack of sexual desire (hypoactive sexual desire disorder) in premenopausal women.
FOR IMMEDIATE RELEASE Contact: Evita Almassi, firstname.lastname@example.org or 425-749-1886
Learn about Addyi (flibanserin) and Vyleesi (bremelanotide), FDA-approved drugs designed to treat hypoactive sexual desire disorder (HSDD) in premenopausal women.